A player in Johnson’s COVID-19 vaccine study
The case is being reviewed through Johnson’s trial knowledge protection oversight committee and clinical and internal protection physicians.
Serious adverse events, such as ailments and accidents, are expected to occur in giant clinical studies, the company said.
“IEGEs are unusual in clinical trials, and it is moderate to expect the number of IGE to accumulate in trials involving a large number of participants,” Johnson said.
AstraZeneca suspended complex testing of his coronavirus vaccine early last month after a player suffered a possible adverse reaction, which resumed in other countries but remains suspended in the United States.
Johnson
“At Johnson’s
Johnson
The company’s vaccine is the fourth to enter complex trials in the United States, however, it is the first candidate to require a single injection and want to be stored at sub-zero temperatures These two points can simply facilitate the distribution of the vaccine. .
The vaccine, developed through Janssen Pharmaceutical Companies, uses the same generation of human adenovirus shown in its Ebola vaccine and its candidates for Zika and HIV vaccines.
Johnson
COVID-19 vaccine trials are being conducted in collaboration with Operation Warp Speed, the federal government’s coronavirus vaccine acceleration program.
However, this approval is expected until at least early 2021. Intermediate effects of Phase 3 trials can take up to two months.
Pfizer and Moderna began Phase 3 testing for their COVID-19 vaccines last July. Officials have warned that a coronavirus vaccine may be in limited capacity by the end of this year.
He and his content are provided “as is”.